A2-73 as a Therapeutic for Insomnia, Anxiety, and Agitation
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/US2017/044111, filed Jul 27, 2017. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,813,242 | A2-73 as a Therapeutic for Insomnia, Anxiety, and Agitation In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence | ||
| US 12,285,403 | A2-73 as a Therapeutic for Insomnia, Anxiety and Agitation In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence | ||
| US 11,337,953 | A2-73 as a Therapeutic for Insomnia, Anxiety, and Agitation In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence | ||
| Application 19/192,118 | A2-73 as a Therapeutic for Insomnia, Anxiety and Agitation Pending Not granted | Anavex Life Sciences Corp. | Pending | Not granted |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Anavex Life Sciences Corp..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.